Symetrica appoints John Zangardi, a former advisor to the US Secretary of Defense for Information Management / Information Technology to its Board of Directors
Symetrica Inc, an innovative, leading radiation detection and identification business in Massachusetts has announced a material business impact from the appointment of John Zangardi, a former advisor to the US Secretary of Defense for Information Management / Information Technology as a Non-Executive Director to the Symetrica Board. Symetrica Inc. operates internationally and has successfully provided the Homeland Security and Military radiation detection market sectors with a wide range of innovative solutions for over 10 years.
August 12, 2019 (BOSTON) PR NEWSWIRE – binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®. The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally. In the Company’s recently completed 1,523-person, multi-center clinical study, 96% of patient samples were processed on the binx io by non-laboratorians in a POC setting.
Micrima, the Bristol-based breast imaging company, has raised £4.4 million in additional equity funding led by Technology Venture Founders, The Angel CoFund (ACF), and Venture Founders plus a group of returning and new individual investors. This brings the total amount raised by Micrima to £10.7m.
Roy Johnson, Micrima’s Executive Chairman, said, “I am very happy to announce the completion of our latest funding round, which provides us with the capital we need to move our initial MARIA product into full commercial launch and follow this swiftly with the enhanced functionality that the system is capable of achieving. The market has been prepared over the past 18 months through the publication of our historical clinical trial data, and attendance at numerous congresses and trade shows to showcase our breakthrough technology. As a result, we have many influential clinicians and partners anticipating the launch of MARIA later this year. We look forward to putting the product we have worked so hard to create into their hands for the first time.”
dotdigital Group Plc (AIM:DOTD), the leading provider of intuitive software as a service (“SaaS”) and managed services to digital marketing professionals, through the ‘dotmailer’ platform, announces that it has completed the acquisition of the COMAPI group of companies. COMAPI (the trading name for Dynmark), a fast-growing business focused on the omni-channel messaging and cloud communication market, has been acquired for a cash consideration of £11 million.
Headquartered in Cheltenham with approximately 30 employees, COMAPI has built a scalable software platform that allows businesses to communicate with their consumers across multiple conversational messaging channels including the growing market for live chat. Comapi’s heavy investment in technology allows it to compete in the CPaaS (communication platform as a service) and ARN markets (alerts, reminders and notification), providing a flexible API (application programming interface) based omni-channel messaging platform and toolkit that facilitates easy integration and rapid deployment to businesses requiring a personalised and two-way customer engagement solution.
COMAPI is a successful brand with strong growth and revenues within the CPaaS market and, with dotdigital’s full support, will continue to work directly with its customers, which include Gap, eBay, TSB, British Airways, Carphone Warehouse and Collect Plus. dotmailer and COMAPI already have numerous shared clients which include Superdry, Hayes Recruitment, Daisy Group and betting giant Ladbrokes.
Symetrica have been announced as the winner of the Venture Category at the British Private Equity & Venture Capital Association’s (BVCA) South West Management Team Awards 2017. Now in their ninth year, the BVCA Management Team Awards recognise and reward brilliant businesses up and down the country that are backed by UK private equity and venture capital investors.
The BVCA’s judges’ commented: “Symetrica has been a pioneer in its radiation detection technology and now has a leading position in homeland security. The judges were impressed with the way Heddwyn Davies had grasped this opportunity in 2016, driving a fourfold increase in sales, notably breaking into the US market, while at the same time bringing out a handheld version of the technology.”
Symetrica will now go forward into the national final to compete against the other UK regions before the national winners are announced at the BVCA Gala Dinner on 30 November in London.
Financing global launch and menu development of Atlas Genetics’ io® molecular testing system
Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.
Development of the Atlas Genetics io® system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in February 2016. This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu. The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics’ cartridge manufacturing partner.
Micrima, the Bristol-based breast imaging company and developer of a ground-breaking and CE Mark approved radiowave breast imaging system, has successfully closed on a new financing round of £2.6m. The new funding will support accelerated development of its patented MARIA technology, which aims to enable breast screening to become safer, more comfortable and more accessible to a larger proportion of the global female population. The company intends to start the commercialisation of its first system towards the end of this year.
“Breast cancer is the most common cause of death in women between the ages of 35 and 55 in Europe and the leading cause of death for women in many countries. The problem is that many tumours are not discovered early enough, largely due to the difficulty in discriminating between cancers and dense tissue using current imaging technology,” said Roy Johnson, Micrima’s Executive Chairman. “Using harmless radiowaves, the MARIA imaging system is capable of detecting tumours in dense tissue and allows routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography. The process takes less than five minutes and avoids painful breast compression.”
TVP portfolio company, Covalent Software, has been acquired by Ideagen Plc, the UK AIM listed provider of information management software to regulated industries.
For Covalent the deal provides significant future growth opportunities in its core financial and public services markets as well as opportunities for the enlarged group to expand its governance, risk and compliance (GRC) presence in healthcare, local government, finance and banking.
The deal marks a successful exit for Covalent’s previous funders. TVP’s Nick Simmonds said: “It has been a pleasure working with Peter McHugh and the team at Covalent Software and we are delighted with the way in which Covalent has developed into a technology leader in the GRC space. We wish the company every success for the future.”
Approval of Chlamydia test for marketing and sale in Europe
Atlas Genetics Ltd, the Bath, UK based, ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has received approval to CE Mark its Chlamydia trachomatis (CT) test to be launched on the Company’s io® platform. By meeting the requirements of the IVD Directive (98/79/EC), the CT test is now cleared for sale within the European Union.
The launch of the io® CT test signals a new era in ultra-rapid molecular diagnostics. This is the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, capable of delivering test results in just 30 minutes. With the speed and accuracy of the io® CT product, the testing and treatment of patients within a single, brief visit to the clinic now becomes a reality.
Object Matrix, the trusted storage partner to the media and entertainment industries, today announces that Sky, Europe’s leading entertainment company with over 21 million customers, has integrated MatrixStore object storage into Avid Interplay production workflows at its headquarters in London.
Sky is Europe’s leading investor in television content, with a combined programming budget of £4.9bn, commissioning its own original programming and entering into strategic partnerships to deliver the best possible TV viewing experience for customers. With production infrastructure often used to capacity, the Sky production team looked to find a solution that could not only scale into future workflows but also take the strain off the editing storage with seamless integration into current workflows.
Symetrica’s Radiation Detection and Identification Technology to be deployed by US Department of Homeland Security
Symetrica has announced that its patented radiation detection and identification technology will be deployed in the latest Handheld Radioisotope Identification Devices (RIIDs) that Smiths Detection Inc. has agreed to supply to the U.S. as part of a contract with the Department of Homeland Security (DHS). Symetrica’s Discovery Technology is at the heart of the Smiths Detection RadSeeker handheld radiation detectors for which the DHS Domestic Nuclear Detection Office (DNDO) recently awarded an IDIQ (indefinite delivery/indefinite quantity) contract with a maximum value of $143 million for the technology, its maintenance and associated training.
Technology Venture Partners the technology venture capital firm has announced the appointment of Richard Green as Non-executive Chairman.
Richard Green joined Kleinwort Benson Development Capital in 1988 and was a founder in 2001 of the spin-out business which became August Equity LLP, where he was the Managing Partner until 2009 and then Chairman until his retirement in April 2014. He is a past chairman of the British Venture Capital Association and is currently a non-executive director of AIM-quoted Qannas Investments Limited, a non-executive director of Northern Venture Trust PLC, a member of the Advisory Board of Finance for Business North East and a member of the Advisory Committee of the European Investment Bank’s Growth Finance Initiative.
The Bristol team of YFM Equity Partners have taken over managing the South West Ventures Fund through a newly formed independent venture capital fund manager, Technology Venture Partners.
The South West Ventures Fund was established as one of the UK’s nine Regional Venture Capital Funds to invest up to £2m of risk capital into high growth small businesses. The fund is now fully invested and the portfolio includes Dynmark, a cloud based mobile intelligence and messaging platform and Micrima, which has developed innovative technology for breast cancer screening based on radiowaves instead of X-rays.
The spin-out will see the South West Ventures Fund continue to be managed by the three founding partners of Technology Venture Partners, Peter Davies, Nick Simmonds and Julian Dennard. Technology Venture Partners will focus on investing in emerging UK technology companies.